In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576

Cancer Research

Volumn 61, Issue 2, 2001, Pages 749-758

  Mistry, Prakash ^a   Stewart, Alistair J ^a   Dangerfield, Wendy ^a   Okiji, Sade ^a   Liddle, Chris ^a   Bootle, Douglas ^a   Plumb, Jane A ^b   Templeton, David ^a   Charlton, Peter ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

^b CRC Department of Medical Oncology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZIDOPINE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; PACLITAXEL; PROTON; RHODAMINE; TARIQUIDAR; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; COLON CANCER; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENERGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACRIDINES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; AZIDES; BINDING, COMPETITIVE; CELL DIVISION; CYCLOSPORINS; DAUNORUBICIN; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; ISOQUINOLINES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; P-GLYCOPROTEIN; PACLITAXEL; QUINOLINES; TETRAHYDROISOQUINOLINES; TIME FACTORS; TREATMENT OUTCOME; TRITIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035863315     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. P-glycoprotein - A mediator of multidrug resistance in tumour cells
2. Biochemistry of multidrug resistance mediated by the multidrug transporter
3. The MDR superfamily of genes and its biological implications
4. Cellular localization of the multidrug resistance gene product in normal human tissues
5. What have we learnt thus far from mice with disrupted P-glycoprotein genes?
6. Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol
7. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP
8. The multidrug resistance protein family
9. ABC transporters: From microorganisms to man
10. Clinical importance of hepatic cytochrome P450 in drug metabolism
11. Human liver microsome metabolism of paclitaxel and drug interactions
12. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
13. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers
14. Clinical trails of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations
15. Clinical trials of P-glycoprotein reversal in solid tumours
16. Pharmacologic approaches to reversing multidrug resistance
17. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833
18. Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro
19. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridone carboxamide derivative
20. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979
21. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative
22. In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance
23. PSC833: Initial clinical results in refractory ovarian cancer patients
24. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP
25. Pharmacological considerations in the modulation of multidrug resistance
26. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives
27. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer
28. Reversal of Adriamycin resistance by verapamil in human ovarian cancer
29. P-glycoprotein efflux pump involved in the mechanism of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport
30. P-glycoprotein possesses a 1.4-dihydropyridine selective drug acceptor site which is allosterically coupled to a Vinca alkaloid selective binding site
31. Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft
32. Reversal of P-glycoprotein mediated multidrug resistance in vivo by XR9576
33. XR9576, a potent modulator of P-glycoprotein-mediated multidrug resistance
34. The molecular interacfion of the high affinity reversal agent XR9576 with P-glycoprotein
35. Pharmacological insights from P-glycoprotein knockout mice
36. Drug resistance: Still on the learning curve
37. An intravenous Phase 1 study with the novel P-glycoprotein-dependent multidrug resistance modulator, XR9576, demonstrates surrogate marker activity in situ